STOCK TITAN

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Metsera (NASDAQ: MTSR), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and metabolic diseases, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Whit Bernard will deliver a presentation on Wednesday, June 11, 2025, from 10:00 to 10:35 AM EDT. Investors and interested parties can access both the live webcast and replay of the presentation through the Events page in the Investors & News section on Metsera's website at investors.metsera.com.
Metsera (NASDAQ: MTSR), una società biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti per l'obesità e le malattie metaboliche, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Salute di Goldman Sachs. Il CEO Whit Bernard terrà una presentazione mercoledì 11 giugno 2025, dalle 10:00 alle 10:35 EDT. Investitori e interessati potranno seguire la diretta streaming e la registrazione della presentazione tramite la pagina Eventi nella sezione Investitori & Notizie sul sito web di Metsera all'indirizzo investors.metsera.com.
Metsera (NASDAQ: MTSR), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos para la obesidad y enfermedades metabólicas, anunció su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs. El CEO Whit Bernard realizará una presentación el miércoles 11 de junio de 2025, de 10:00 a 10:35 AM EDT. Inversionistas y partes interesadas podrán acceder tanto a la transmisión en vivo como a la repetición de la presentación a través de la página de Eventos en la sección de Inversionistas y Noticias en el sitio web de Metsera en investors.metsera.com.
Metsera(NASDAQ: MTSR)는 비만 및 대사 질환 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 골드만삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 휘트 버나드는 2025년 6월 11일 수요일 오전 10시부터 10시 35분(EDT)까지 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Metsera 웹사이트의 투자자 및 뉴스 섹션 내 이벤트 페이지를 통해 생중계 및 다시보기 영상을 시청할 수 있습니다. (웹사이트 주소: investors.metsera.com)
Metsera (NASDAQ : MTSR), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements contre l'obésité et les maladies métaboliques, a annoncé sa participation à la 46e conférence annuelle mondiale sur la santé de Goldman Sachs. Le PDG Whit Bernard présentera mercredi 11 juin 2025, de 10h00 à 10h35 EDT. Les investisseurs et les parties intéressées peuvent accéder à la fois au webinaire en direct et à la rediffusion de la présentation via la page Événements dans la section Investisseurs & Actualités sur le site web de Metsera à l'adresse investors.metsera.com.
Metsera (NASDAQ: MTSR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für Fettleibigkeit und Stoffwechselerkrankungen spezialisiert hat, gab seine Teilnahme an der 46. jährlichen Global Healthcare Conference von Goldman Sachs bekannt. CEO Whit Bernard wird am Mittwoch, den 11. Juni 2025, von 10:00 bis 10:35 Uhr EDT eine Präsentation halten. Investoren und Interessierte können sowohl das Live-Webcast als auch die Wiederholung der Präsentation über die Veranstaltungsseite im Bereich Investoren & Nachrichten auf der Website von Metsera unter investors.metsera.com abrufen.
Positive
  • None.
Negative
  • None.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT.

A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com.

About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.

Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the “Email Alerts” option on the Investors & Media page and submitting your email address.

Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation in the Goldman Sachs 46th Annual Global Healthcare Conference, its research and development activities, and its product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera’s business outlined in Metsera’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera’s actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Jono Emmett
Metsera
media@metsera.com


FAQ

When is Metsera (MTSR) presenting at the Goldman Sachs Healthcare Conference 2025?

Metsera will present on Wednesday, June 11, 2025, from 10:00 to 10:35 AM EDT.

Who will represent Metsera (MTSR) at the Goldman Sachs Healthcare Conference?

Whit Bernard, Metsera's Chief Executive Officer, will present at the conference.

How can I watch Metsera's (MTSR) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be accessed through a live webcast and replay on Metsera's website at investors.metsera.com under the Events page in the Investors & News section.

What is Metsera's (MTSR) main focus as a company?

Metsera is a clinical-stage biopharmaceutical company developing next-generation medicines for obesity and metabolic diseases.
Metsera

NASDAQ:MTSR

MTSR Rankings

MTSR Latest News

MTSR Stock Data

3.00B
17.19M
0.93%
38.56%
3.99%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK